InnoCare wins China CDE approval for registrational Phase III mesutoclax — orelabrutinib trial in r/r MZL

China’s NMPA drug regulator cleared InnoCare’s registrational Phase III trial of mesutoclax with orelabrutinib in relapsed/refractory MZL. Study targets patients who received at least one prior therapy, supporting a potential label-expansion path in China. Mesutoclax-orelabrutinib holds Breakthrough Therapy Designation in China for previously treated MZL; InnoCare cited 100% ORR from ASCO 2026 data. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InnoCare Pharma Ltd. published the original content used to generate this news brief via (Ref. ID: 202610122358PRIMZONEFULLFEED9844389) on October 13, 2026, and is solely responsible for the information contained therein. (C)